Palvella Therapeutics (PVLA) Cost of Revenue (2013 - 2014)
Palvella Therapeutics' (PVLA) quarterly Cost of Revenue came in at $18.0 in Q3 2014, up 50.0% year-on-year from $12.0 in Q3 2013, and up 50.0% on a QoQ basis from $12.0 in Q3 2013.
Palvella Therapeutics (PVLA) Cost of Revenue (2013 - 2014) Analysis & Trends
Palvella Therapeutics (PVLA) has 2 years of Cost of Revenue data on file, last reported at $18.0 in Q3 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 167.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 392.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 296.00 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 145.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Palvella Therapeutics | 1.88 Bn | 1.61 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2014 | 18.00 |
| Sep 30, 2014 | 18.00 |
| Sep 30, 2013 | 12.00 |
| Sep 30, 2013 | 12.00 |